MMV is committed to diversity, equity and inclusion (DEI) both internally as well as in its programmatic activities.

DEI within MMV

Within its organization, MMV values diversity, recognizing that diversity and inclusion are not only an essential component of equity, but that they also enhance team and organizational performance.

In 2021, MMV’s CEO created a study group to support progress in mainstreaming gender equity, diversity and inclusion in policies and practices. The study group acts as a cross-departmental group helping MMV create a diverse, productive and inclusive workplace.

→Read MMV's policy on Diversity, Equity and Inclusion

DEI in MMV’s programmatic work

MMV’s programmatic activities reflect its dedication to DEI, and are ultimately aimed at eliminating gender biases in malaria bio-medical and clinical research.

Malaria means a heightened risk of morbidity and mortality for pregnant women and girls, as well as an increased probability of mortality and short-to-long-term health risks for their newborn babies.¹ This contributes to keeping women and girls away from school and work, exacerbating gender inequalities in educational attainment and in the workplace, and ultimately intensifying gendered power imbalances in society.

As a recognized leader in antimalarial drug discovery, development and delivery, MMV aims to provide informed therapeutic choices for malaria treatment and protection across all genders and age categories, including pregnant and lactating women.

→For more information read MMV's MiMBa strategy

1. WHO. More pregnant women and children protected from malaria, but accelerated efforts and funding needed to reinvigorate global response, WHO report shows (2019).